Aura Biosciences, Inc. 4

Sapna Srivastava received 15,000 RSU shares and stock options for 30,000 shares of Aura Biosciences common stock at a $6.21 exercise price as equity compensation.

On June 11, 2026, reporting person Sapna Srivastava of Aura Biosciences, Inc. received an equity compensation grant consisting of 15,000 shares of common stock pursuant to a restricted stock unit (RSU) award and a stock option to purchase 30,000 shares of common stock at an exercise price of $6.21 per share under the company’s 2021 Stock Option and Incentive Plan. The RSUs will vest in full upon the earlier of June 11, 2027 or the next annual meeting of stockholders, subject to continued service, and the stock option is subject to the same vesting schedule with an expiration date of June 11, 2036. Following these awards, Srivastava directly holds 38,500 shares of common stock and derivative rights to acquire an additional 30,000 shares. Using the option exercise price as a proxy for the current share price, the RSU grant is valued at approximately $93,150 and the option grant represents potential value of about $186,300, bringing the estimated value of her direct and derivative equity interest to roughly $424,000, all of which reflects routine director/insider compensation rather than an open-market purchase or sale.

Filing Facts

CIK

1501796

Ticker

AURA

Form

4

Source Type

fda

Accession

0001193125-26-271170

Alert Tier

5